— Company study aims to determine efficacy of diabetes treatment Las Vegas, Nevada, July 7, 2015, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”) is pleased to announce that efforts are underway to commence clinical trials of its…
LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC), (the “Company”) is pleased to announce it has retained TDM Financial to provide marketing, outreach, and consulting services. TDM Financial owns and operates the SECFilings.com website, a leading financial network with over 600,000…
LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC), (the “Company”) is pleased to announce additional results of the ongoing analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. The pilot clinical discovery phase trial in two diabetic subjects…
LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC) (the “Company”) is pleased to announce that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial. The pilot clinical discovery phase trial…
LAS VEGAS, NV–Cell MedX Corp. (OTC PINK: CMXC) (OTCQB: CMXC), (the “Company”) is pleased to announce that the Company has received an approval from the OTC Markets to upgrade to the OTCQB venture stage marketplace. The Company will transition from…
Cell MedX Corp. (OTC PINK: CMXC), (the “Company”) has become aware of a paid report on the Company prepared and published by The Moskowitz Report dated Winter 2015, and additional reports on the Company prepared by James E. Brumley as…
LAS VEGAS, NV–Cell MedX Corp. (OTC: CMXC), (the “Company”) announced today that the Company has engaged The Metabolomics Innovation Centre at the University of Alberta (“TMIC”) to conduct metabolomics profiling of blood samples collected during the discovery phase of the…
Las Vegas, Nevada, January 5, 2015, Cell MedX Corp. (OTC:CMXC), (the “Company”) announced today that the Company has scheduled the commencement of its pilot trial of the e-balance Technology for January 9, 2015. The trial will be conducted on human…
LAS VEGAS, NV–(Marketwired – Dec 24, 2014) – Cell MedX Corp. (OTCQB: CMXC), (the “Company”) announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC. The decision…
LAS VEGAS, NV–Cell MedX Corp. (OTCQB: CMXC) (the “Company”) is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. (“Avyonce”). Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to…